FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

Conversion From Accelerated to Full Approval Reinforces Blincyto as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission THOUSAND OAKS, Calif., June 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news